(Q53153270)

English

Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.

scientific article published in January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George J Kontoghiorghes

3

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

author name string

Annita Kolnagou

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

Marios Kleanthous

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

publication date

1 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

35

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

186-198

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease: the role of natural and synthetic chelators

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Selective iron chelation in Friedreich ataxia: biologic and clinical implications

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation.

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/de

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Survival and disease complications in thalassemia major.

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576153

21 January 2018

Identifiers

10.3109/03630269.2011.576153

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/21599431

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53153270&oldid=1584420721"